Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
emtricitabine-tenofovir alafenamide
emtricitabine-tenofovir alafenamide
- Non-formulary AIDS Drugs Formulary
- Therapeutic Interchange
Last updated: Oct. 11, 2017
- Black Box Warning: Emtricitabine: Lactic Acidosis, Severe Hepatomegaly
- Black Box Warning: Tenofovir: Lactic acidosis, severe hepatomegaly; hepB co-infection
If ordered for inpatients, dispense individual components.
Inpatients are encouraged to use home supply. Defer initiation to outpatient setting.
Descovy contains the tenofovir salt -- tenofovir alafenamide. This dosage form causes less renal impairment over several months exposure or longer than dose the tenofovir disoproxil fumarate (TDF).
As of Aug 2016, the alafenamide salt is not available as a separate drug. ID subcommittee recommended not to substitute the TDF salt for the alatenamide automatically.Descovy will be non-formulary once the alafenamide salt is available as a separate agent.Not An Automatic Interchange
(Unboosted) tenofovir alafenamide 25 mg = tenofovir disoproxil fumarate 300 mg
Note that the 2 tenofovir salts have different recommendations on use in renal insufficiency.
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
emtricitabine-tenofovir alafenamide (Descovy)
emtricitabine (Emtriva) AND tenofovir alafenamide (Vemlidy)
Reviewed: 23 August 2016 (Descovy), and 27 June 2017 (Descovy)